Avidity and titers of the antibody response to two inactivated poliovirus vaccines with different antigen content

The inactivated poliovirus vaccine is heat stabile, gives high serum IgG concentrations but less pronounced mucosal immunity and must be given as repeated injections. A new enhanced‐potency Dutch inactivated vaccine could circumvent these difficulties. We compared antibody concentrations measured as neutralization or ELISA titers, and avidity of serum and salivary antibodies in children vaccinated with three doses of the earlier Swedish vaccine given over nine months or the new antigen‐rich vaccine. After three doses, but not after two, serum neutralization titers for type 1 and type 3 poliovirus were higher using the new vaccine but secretory IgA levels in saliva were similar. The avidity of the serum IgC antibodies was significantly higher after two doses of the new vaccine than after three doses of the old. Thus the new vaccine gives excellent antibody responses of high titers and avidities, but should preferably be given in three doses.

[1]  L. Hanson,et al.  Comparison of Serum and Salivary Antibodies in Children Vaccinated with Oral Live or Parenteral Inactivated Poliovirus Vaccines of Different Antigen Concentrations , 1991, Acta paediatrica Scandinavica.

[2]  S. Jeansson,et al.  Specific Antibodies to Poliovirus Type I in Breastmilk of Unvaccinated Mothers before and Seven Years after Start of Community‐Wide Vaccination of Their Infants with Live, Oral Poliovirus Vaccine , 1991, Acta paediatrica Scandinavica.

[3]  A. McBean,et al.  Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. , 1990, The Journal of infectious diseases.

[4]  M. Böttiger Polio immunity to killed vaccine: an 18-year follow-up. , 1990, Vaccine.

[5]  P. Ogra,et al.  Poliovirus vaccines. A continuing challenge. , 1990, Pediatric clinics of North America.

[6]  A. Beale Polio vaccines: time for a change in immunisation policy? , 1990, The Lancet.

[7]  L. Hanson,et al.  Avidity of IgA Antibody to Escherichia coli Polysaccharide and Diphtheria Toxin in Breast Milk from Swedish and Pakistani Mothers , 1988, Scandinavian journal of immunology.

[8]  L. Hanson,et al.  Secretory and serum immunoglobulin class-specific antibodies to poliovirus after vaccination. , 1985, The Journal of infectious diseases.

[9]  C. Alving,et al.  Heterogeneity of lipid A. , 1984, Reviews of infectious diseases.

[10]  M. Böttiger Long-term immunity following vaccination with killed poliovirus vaccine in Sweden, a country with no circulating poliovirus. , 1984, Reviews of infectious diseases.

[11]  J. Salk,et al.  One-dose immunization against paralytic poliomyelitis using a noninfectious vaccine. , 1984, Reviews of infectious diseases.

[12]  R. Henderson The Expanded Programme on Immunization of the World Health Organization. , 1984, Reviews of infectious diseases.

[13]  M. Steward The biolgoical significance of antibody affinity. , 1981, Immunology today.

[14]  H. Lundbeck,et al.  The immune response to vaccination with inactivated poliovirus vaccine in Sweden. , 1966, Acta pathologica et microbiologica Scandinavica.

[15]  J. Kapsenberg,et al.  The spread of wild poliovirus in the well-vaccinated Netherlands in connection with the 1978 epidemic. , 1984, Progress in medical virology. Fortschritte der medizinischen Virusforschung. Progres en virologie medicale.

[16]  K. Lapinleimu,et al.  Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis. , 1981, Developments in biological standardization.

[17]  J. V. van Herwaarden,et al.  The production of inactivated poliovaccine on serially cultivated kidney cells from captive-bred monkeys. , 1980, Developments in biological standardization.

[18]  P. Saliou,et al.  Killed poliovirus antigen titration in humans. , 1978, Developments in biological standardization.

[19]  M. Böttiger,et al.  Seroimmunity to poliomyelitis in Sweden after the use of inactivated poliovirus vaccine for 10 years. , 1972, Bulletin of the World Health Organization.